28:I[164923,["/_next/static/immutable/chunks/0x-9rc1bm-510.js","/_next/static/immutable/chunks/0u73ovrok9bmr.js","/_next/static/immutable/chunks/3t9ifrnugpnlb.js","/_next/static/immutable/chunks/3gdp0tzp2t65u.js","/_next/static/immutable/chunks/0qexc5596g7lf.js","/_next/static/immutable/chunks/3nkl8euu6dycn.js","/_next/static/immutable/chunks/28p3k9kvs3dfa.js","/_next/static/immutable/chunks/04j_o97cgxn2x.js","/_next/static/immutable/chunks/18bybpoq919w1.js"],"ClinicalTrialDetail"] 25:["$","script","1",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Clinical Trials\",\"item\":\"https://clareohealth.com/clinical-trials\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Neuroendocrine Carcinoma\",\"item\":\"https://clareohealth.com/clinical-trials/condition/neuroendocrine-carcinoma\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"NCT01121939\",\"item\":\"https://clareohealth.com/clinical-trials/NCT01121939\"}]}"}}] 26:["$","script","2",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"MedicalWebPage\",\"name\":\"Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers\",\"description\":\"This clinical trial tested a combination of three drugs—Bevacizumab, Pertuzumab, and Sandostatin—on patients with advanced neuroendocrine cancers. The goal was to see how effective this combination is in treating this type of cancer.\",\"url\":\"https://clareohealth.com/clinical-trials/NCT01121939\",\"mainEntity\":{\"@id\":\"https://clareohealth.com/clinical-trials/NCT01121939\"},\"specialty\":{\"@type\":\"MedicalSpecialty\",\"name\":\"Clinical Research\"},\"audience\":{\"@type\":\"PeopleAudience\",\"audienceType\":\"Patients and Caregivers\"},\"lastReviewed\":\"2016-02-05\",\"medicalAudience\":{\"@type\":\"MedicalAudience\",\"audienceType\":\"Patient\"},\"reviewedBy\":{\"@type\":\"Organization\",\"name\":\"ClinicalTrials.gov\",\"url\":\"https://clinicaltrials.gov\"}}"}}] 29:T1450,Inclusion Criteria: 1. Patients with biopsy-proven advanced, unresectable or metastatic, well-differentiated (or low-grade) neuroendocrine carcinoma, including typical carcinoid, pancreatic islet cell and other well-differentiated neuroendocrine carcinomas. 2. Patients with documented evidence of disease progression. 3. Patients currently receiving or previously treated with single agent Sandostatin LAR® are eligible. 4. Patients must have \>=1 unidimensional measurable lesion definable by MRI or CT scan. Disease must be measurable per RECIST version 1.1 criteria. 5. Left Ventricular Ejection Fraction (LVEF) \>=50% as determined by either ECHO or MUGA \<=6 weeks prior to study entry. 6. An ECOG Performance Status of 0-2. 7. Laboratory values as follows: * ANC \>=1500/μL * Hgb \>=9 g/dL * Platelets \>=100,000/μL * AST/SGOT \<=2.5 x ULN or \<=5.0 x ULN in patients with liver metastases * ALT/SGPT \<=2.5 x ULN or \<=5.0 x ULN in patients with liver metastases * Bilirubin \<=1.5 x ULN * Creatinine \<=2.0 mg/dL or calculated creatinine clearance \>=50 mL/min 8. Patients \>=18 years of age. 9. Patients must have a life expectancy \>12 weeks. 10. Patient must be accessible for treatment and follow-up. 11. Women of childbearing potential must have a negative serum or urine pregnancy test performed \<=7 days prior to start of treatment. Women of childbearing potential must use effective birth control measures during treatment. If a woman becomes pregnant or suspects she is pregnant while participating in this study, she must agree to inform her treating physician immediately. 12. Patients must be able to understand the nature of the study and give written informed consent, and comply with study requirements Exclusion Criteria: 1. Patients with poorly differentiated neuroendocrine carcinoma, highgrade neuroendocrine carcinoma, adenocarcinoid, goblet cell carcinoid, atypical carcinoid, anaplastic carcinoid, and small cell carcinoma are not eligible. 2. Previous treatment with VEGF or EGFR inhibitors. 3. Cytotoxic chemotherapy, immunotherapy or radiotherapy \<=4 weeks prior to study entry. 4. History or known presence of central nervous system (CNS) metastases. 5. Patients who have had a major surgical procedure (not including mediastinoscopy), open biopsy, or significant traumatic injury \<=4 weeks prior to beginning treatment. 6. Female patients who are pregnant or lactating. 7. History of hypersensitivity to active or inactive excipients of any component of treatment (bevacizumab, sandostatin, and/or pertuzumab). 8. Patients with proteinuria at screening as demonstrated by urine dipstick for proteinuria \>=2+ (patients discovered to have \>=2+ proteinuria on dipstick urinalysis at baseline should undergo a 24-hour urine collection, and must demonstrate \<=1 g of protein/24 hours to be eligible). 9. Patients with a serious non-healing wound, active ulcer, or untreated bone fracture. 10. Patients with evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation). 11. Patients with history of hematemesis or hemoptysis (defined as having bright red blood of ½ teaspoon or more per episode) \<=1 month prior to study enrollment. 12. History of myocardial infarction or unstable angina \<=6 months prior to beginning treatment. 13. Inadequately controlled hypertension (defined as systolic blood pressure \>150 mmHg and /or diastolic blood pressure \>100 mmHg while on antihypertensive medications). Initiation of antihypertensive agents is permitted provided adequate control is documented at least 1 week prior to Day of study treatment. 14. New York Heart Association (NYHA) grade II or greater congestive heart failure (CHF). 15. Serious cardiac arrhythmia requiring medication. 16. Significant vascular disease (e.g., aortic aneurysm requiring surgical repair, or recent peripheral arterial thrombosis) \<=6 months prior to Day 1 of treatment. 17. History of stroke or transient ischemic attack \<=6 months prior to beginning treatment. 18. Any prior history of hypertensive crisis or hypertensive encephalopathy. 19. History of abdominal fistula or gastrointestinal perforation \<=6 months prior to Day 1 of beginning treatment. 20. Concurrent severe, intercurrent illness including, but not limited to, ongoing or active infection, or psychiatric illness/social situations that would limit compliance with study requirements. 21. Any known positive test for human immunodeficiency virus, hepatitis C virus or acute or chronic hepatitis B infection. 22. Mental condition that would prevent patient comprehension of the nature of, and risk associated with, the study. 23. Use of any non-approved or investigational agent \<=28 days prior to administration of the first dose of study drug. Patients may not receive any other investigational or anti-cancer treatments while participating in this study. 24. Past or current history of neoplasm other than the entry diagnosis with the exception of treated non-melanoma skin cancer or carcinoma in situ of the cervix, or other cancers cured by local therapy alone and a DFS \>=5 years. 25. Infection requiring IV antibiotics.27:["$","$L28",null,{"trial":{"nctId":"NCT01121939","briefTitle":"Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers","officialTitle":"Phase II Study of the Combination of Bevacizumab, Pertuzumab, and Sandostatin for Patients With Advanced Neuroendocrine Cancers.","briefSummary":"The purpose of this Phase II trial will be to define the activity of a VEGF inhibitor\n\nbevacizumab, HER1/HER2 inhibitor pertuzumab, and sandostatin for patients with\n\nadvanced neuroendocrine cancers. In particular, the efficacy of bevacizumab and\n\npertuzumab treatment is of great interest. The primary endpoint of this trial will be\n\nresponse rate. Toxicity and progression-free survival will be obtained and evaluated.","detailedDescription":"* To determine overall response rate of patients with low grade neuroendocrine cancer when treated with the combination of bevacizumab, pertuzumab and sandostatin LAR®.\n* To determine the disease control rate (objective response + stable disease), time to treatment progression, progression-free survival, and overall survival in patients with advanced low grade neuroendocrine cancer when treated with bevacizumab, pertuzumab and Sandostatin LAR® treatment.\n* To define the toxicity and safety of the combination of bevacizumab, pertuzumab and Sandostatin LAR® when used in patients with advanced low grade neuroendocrine cancer.","overallStatus":"COMPLETED","phase":"PHASE2","studyType":"INTERVENTIONAL","conditions":["Neuroendocrine Carcinoma"],"interventions":[{"type":"DRUG","name":"Bevacizumab","description":"15 mg/kg IV Day 1. The first dose should be administered over\n\n90 minutes. If no adverse reactions occur after the initial dose, the second dose should\n\nbe administered over a minimum of 60 minutes. If no adverse reactions occur after the\n\nsecond dose, all subsequent doses should be administered over a minimum of 30\n\nminutes. Bevacizumab will be infused prior to pertuzumab."},{"type":"DRUG","name":"Pertuzumab","description":"840 mg IV loading dose infused over 60 minutes. The loading dose is given on Cycle 1, Day 1 or as below. Subsequent doses of pertuzumab are 420 mg IV. If the patient tolerates the initial infusion over 60 minutes, the patient may receive subsequent infusions over 30 minutes. Otherwise, pertuzumab should be infused over 60 minutes. Patients should be observed for 30 minutes after completing the pertuzumab infusion.\n\nIf a patient misses a dose of pertuzumab for 1 cycle (i.e., 2 sequential cycles or administrations are 6 weeks or more apart), a re-loading dose (840 mg) of pertuzumab should be given. If re-loading pertuzumab is administered, subsequent doses of 420 mg will then be given every 3 weeks, starting 3 weeks later."},{"type":"DRUG","name":"Sandostatin LAR® Depot","description":"30 mg will be given every 28 days by IM injection. The dose of sandostatin may be increased, at the discretion of the treating physician, if necessary to control symptoms related to tumor secretion of vasoactive peptides."}],"keywords":["advanced neuroendocrine","Gastrointestinal","Bevacizumab","Avastin","Pertuzumab","Omnitarg","2C4","Sandostatin","Octreotide"],"locations":[{"facility":"Florida Cancer Specialists","city":"Fort Myers","state":"Florida","country":"United States","zip":"33901","lat":26.62168,"lng":-81.84059},{"facility":"Florida Hospital Cancer Institute","city":"Orlando","state":"Florida","country":"United States","zip":"32804","lat":28.53834,"lng":-81.37924},{"facility":"Medical Oncology Associates of Augusta","city":"Augusta","state":"Georgia","country":"United States","zip":"30901","lat":33.47097,"lng":-81.97484},{"facility":"Baptist Medical Center East","city":"Louisville","state":"Kentucky","country":"United States","zip":"40207","lat":38.25424,"lng":-85.75941},{"facility":"Grand Rapids Oncology Program","city":"Grand Rapids","state":"Michigan","country":"United States","zip":"49503","lat":42.96336,"lng":-85.66809},{"facility":"Research Medical Center","city":"Kansas City","state":"Missouri","country":"United States","zip":"64132","lat":39.09973,"lng":-94.57857},{"facility":"Hematology-Oncology Associates of Northern NJ","city":"Morristown","state":"New Jersey","country":"United States","zip":"07960","lat":40.79677,"lng":-74.48154},{"facility":"Oncology Hematology Care, Inc","city":"Cincinnati","state":"Ohio","country":"United States","zip":"45242","lat":39.12711,"lng":-84.51439},{"facility":"Tennessee Oncology Associates","city":"Nashville","state":"Tennessee","country":"United States","zip":"37203","lat":36.16589,"lng":-86.78444}],"eligibilityCriteria":"$29","minAge":18,"maxAge":null,"sex":"ALL","healthyVolunteers":false,"leadSponsor":"SCRI Development Innovations, LLC","collaborators":["Genentech, Inc."],"contacts":null,"startDate":"$D2010-05-01T00:00:00.000Z","completionDate":"$D2015-08-01T00:00:00.000Z","primaryCompletionDate":"$D2015-02-01T00:00:00.000Z","firstPostDate":"$D2010-05-12T00:00:00.000Z","lastUpdatePostDate":"$D2016-02-05T00:00:00.000Z","enrollmentCount":43,"enrollmentType":"ACTUAL","aiSummary":{"summary":"This clinical trial tested a combination of three drugs—Bevacizumab, Pertuzumab, and Sandostatin—on patients with advanced neuroendocrine cancers. The goal was to see how effective this combination is in treating this type of cancer.","mayQualifyIf":["You are at least 18 years old and have a diagnosis of advanced, unresectable or metastatic neuroendocrine carcinoma.","You have evidence that your cancer is progressing and can provide measurable test results.","You have a good overall health status, with a life expectancy of more than 12 weeks."],"likelyWontQualifyIf":["You have poorly differentiated neuroendocrine carcinoma or other specific types of cancer that are not eligible.","You have received certain previous cancer treatments like chemotherapy or radiotherapy within the last 4 weeks.","You have serious heart conditions or uncontrolled high blood pressure."],"whatParticipatingInvolves":["You will receive Bevacizumab and Pertuzumab through an IV infusion, starting with longer infusion times that may become shorter if tolerated.","You will also receive Sandostatin as an injection every 28 days.","You will need to attend regular visits for these treatments and monitoring, including tests like MRI or CT scans.","You must agree to follow specific health guidelines and report any side effects during the study."]},"aiSummaryGeneratedAt":"$D2026-04-27T03:20:30.844Z","id":"249c90c6-eccb-41b6-b151-0305c57e096e","createdAt":"$D2026-03-23T05:38:13.880Z","updatedAt":"$D2026-04-27T03:20:30.844Z"}}]

What this study is about